CD274 and nasopharyngeal carcinoma: Future clinical studies for stage II NPC requiring CCRT could explore the use of targeted drugs like nimotuzumab or PD-1/PD-L1 monoclonal antibodies as alternatives to platinum-based chemotherapy, aiming to reduce toxicity without compromising efficacy.